Subtype-selective antagonists of the peripheral-type (CCK-A) and the central-type (CCK-6) cholecystokinin (CCK) receptors were employed to determine the receptor subtype(s) mediating the modulatory actions of CCK on dopamine-induced changes in exploratory activity at three sites in the mesolimbic pathway of the rat. The CCK-A antagonist L-364,718 (10 ng) blocked CCK potentiation of dopamine-induced hyperlocomotion in the medial posterior nucleus accumbens. The CCK-B antagonist
Cl-988 (20 ng) blocked CCK inhibition of dopamine-induced hyperlocomotion in the anterior nucleus accumbens.
The CCK-B antagonists Cl-988 (20 ng) and L-365,260 (10 ng) blocked CCK potentiation of dopamine-induced hypolocomotion in the ventral tegmental area. These data indicate a CCK-B pharmacology in the cell body and anterior terminal field, and a CCK-A pharmacology in the posterior terminal field, of the mesolimbic dopamine pathway.
Behavioral analyses using the selective CCK antagonists did not detect a contribution of endogenous CCK to exploratory locomotion.
L-364,71 8 (10 ng), L-365,260 (10 ng), and Cl-988 (20 ng or 2 rg), microinjected into the medial posterior nucleus accumbens, anterior nucleus accumbens, or ventral tegmental area, had no effect on baseline exploratory locomotion or on dopamine-induced changes in exploratory locomotion.
Using a dark-induced hyperlocomotion paradigm, the CCK antagonists at these doses at these sites and intraperitoneally had no effect on the high levels of exploratory locomotor activity exhibited by the rats in the dark testing environment, or the lower levels of exploratory activity in the lighted environment.
Endogenous CCK may not be released during dopamine-induced hyperlocomotion or dark-induced hyperlocomotion, or endogenous CCK may not contribute significantly to exploratory behaviors mediated through the mesolimbic dopamine pathway. Utilization of these potent, selective, nonpeptide CCK antagonists, with the doses, vehicles, and routes of administration developed in the present studies, will guide further investigations into the role of endogenous CCK in other facets of mesolimbic function.
Cholecystokinin (CCK) coexists with dopamine (DA) in ventral tegmental neurons, projecting to the medial posterior nucleus accumbens, media1 olfactory tubercle, and medial septum in the rat brain (Hdkfelt et al., 1980a,b; Fallon et al., 1983) . mRNA for CCK is seen in cell bodies of the ventral tegmentum and substantia nigra zona compacta of the rat, cat, monkey, and human (Hokfelt et al., 1985; Ingram et al., 1989; Palacios et al., 1989; Savasta et al., 1989; Seroogy et al., 1989a,b; Burgunder and Young, 1990; Cottingham et al., 1990; Jayaraman et al., 1990; Schalling et al., 1990; Schiffmann and Vanderhaeghen, 199 1) . Retrograde tracing and lesions studies in the rat indicate that a large proportion of the CCK content of the medial posterior nucleus accumbens derives from mesolimbic projections of ventral tegmental neurons, while CCK in the anterior nucleus accumbens and caudate nucleus derives from cortical cell bodies (Hokfelt et al., 1980b (Hokfelt et al., , 1988 Studler et al., 1981; Marley et al., 1982; Meyer et al., 1982; Fallon et al., 1983; Seroogy et al., 1989a; Adams and Fisher, 1990) . The CCK-DA coexistence in rat brain therefore provides an excellent model system for investigating the functional interactions between coexisting neurotransmitters, with the mesolimbic projection from the ventral tegmental cell bodies to the medial posterior nucleus accumbens being the pathway of the CCK-DA coexistence, while the midbrain dopaminergic projections to the anterior nucleus accumbens and caudate nucleus are non-CCK-containing control pathways.
Interactions between CCK and DA have been investigated using immunocytochemical, mRNA, biochemical, receptor binding, second messenger, release, neurophysiological, and behavioral techniques (Crawley, 199 1) . Differential actions of CCK have been reported at the ventral tegmental soma, the posterior nucleus accumbens, and the anterior nucleus accumbens. At the cell body, CCK is excitatory alone, while potentiating the inhibitory actions of DA and the dopaminergic agonist apomorphine (Skirboll et al., 1981; Hommer et al., 1985; Brodie and Dunwiddie, 1987; Freeman and Bunney, 1987; Freeman and Chiodo, 1988; Stittsworth and Mueller, 1990; Zhang et al., 199 1) . In the nucleus accumbens, CCK blocks the inhibitory effects of DA (White and Wang, 1984; Yim and Mogenson, 1991) . Release studies in slice preparations suggest that CCK potentiates the release of DA in the posterior nucleus accumbens, while CCK inhibits the release of DA in the anterior nucleus accumbens (Altar et al., 1988; Marshall et al., 199 1) . Behavioral studies similarly indicate that CCK potentiates DA-mediated hyperlocomotion and self-stimulation in the posterior nucleus accumbens, while inhibiting DA-mediated behaviors in the anterior nucleus accumbens (Crawley et al., 1985b; De Witte et al., 1987; Weiss et al., 1988; Dauge et al., 1989; Vaccarino and Rankin, 1989; Vaccarino and Vaccarino, 1989) . In addition, CCK potentiates DA-mediated hypolocomotion in the ventral tegmental area (Crawley, 1989b) . medial posterior nucleus accumbens, anterior nucleus accumbens, or ventral tegmental area.
Materials and Methods
Male Sprague-Dawley rats, 250 gm starting weight, were anesthetized with chloral hydrate and prepared for stereotaxic surgery in accordance with the NIH Guide for the Care and Use of Laboratory Animals. Sterile hypodermic stainless steel guide cannulas (24 gauge) were implanted bilaterally into the medial posterior nucleus accumbens, the anterior nucleus accumbens, or the ventral tegmental area, according to the atlas of Paxinos and Watson (1986) , as previously described (Crawley et al., 1985a,b; Crawley, 1989b) . Coordinates were (1) posterior nucleus accumbens: 1.2 mm rostra1 to bregma, & 1.2 mm lateral to the midline, and 6.0 mm ventral to the skull; (2) anterior nucleus accumbens: 2.5 mm rostra1 to bregma, + 1.2 mm lateral to the midline, 6.5 mm ventral to the surface ofthe skull; and (3) ventral tegmental area: 5.8 mm caudal to bregma, k-O.5 mm lateral to the midline, 6.5 mm ventral to the surface of the skull. A stylet prepared from 3 I gauge tubing was inserted flush with the ventral surface of each cannula, to seal the indwelling guide cannula.
Two subtypes of CCK receptors have been described (Moran et al., 1986) . The peripheral-type or CCK-A receptor is found in the pancreas, gall bladder, vagus nerve, and some brain regions including the nucleus tractus solitarius, area postrema, interpeduncular nucleus, and posterior nucleus accumbens (Moran et al., 1986; Hill et al., 1987 Hill et al., , 1990 Rovati and Makovec, 1988; Barrett et al., 1989) . Agonist binding at the CCK-A receptor follows the potency profile sulfated CCK octapeptide >>) unsulfated CCK octapeptide > CCK tetrapeptide, and is blocked by the selective, high-affinity compound L-364,7 18 (Chang and Lotti, 1986) . The central-type or CCK-B receptor is found throughout the CNS (Moran et al., 1986; Peleprat et al., 1987; Hill et al., 1990) . Agonist binding at the CCK-B receptor follows the profile sulfated CCK octapeptide 2 unsulfated CCK octapeptide 2 CCK tetrapeptide, and is blocked by the selective, high-affinity compounds L-365,260 and (X-988 (Lotti and Chang, 1989; Hughes et al., 1990) . Differential agonist effects ofCCK fragments and analogs have been reported, with a CCK-A receptor subtype pharmacology indicated in the medial posterior nucleus accumbens, as compared to a CCK-B receptor subtype pharmacology indicated in the anterior nucleus accumbens and ventral tegmental area Vickroy et al., 1988; Altar and Boyar, 1989; Crawley, 1989b; Dauge et al., 1990; Marshall et al., 199 1) . The present studies were designed to utilize the recently developed, highly selective antagonists of the CCK-A and CCK-B receptor subtypes, to determine definitively the receptor subtype(s) mediating the modulatory actions of CCK on DA-induced exploratory activity. In addition, issues of dose, vehicle, time course, route of administration, and optimal behavioral paradigms are addressed, as the present studies represent the first use of these new CCK antagonists for intracerebral microinjection into the mesolimbic pathway in awake, behaving rats. The role of endogenous CCK in dopaminergic pathways can effectively be tested with the selective, high-affinity CCK receptor antagonists. The present studies quantitated the contribution of endogenous CCK to exploratory behaviors, by administering CCK-A or CCK-B antagonists alone, or in combination with DA, into the medial posterior nucleus accumbens, the anterior nucleus accumbens, and the ventral tegmental area. In addition, dark-induced hyperlocomotion, a behavioral paradigm designed to mimic DA-induced hyperlocomotion nonpharmacologically, was employed in the present studies of CCK antagonists, to evaluate the contribution of mesolimbic CCK to darkinduced hyperlocomotion. The dark-induced hyperlocomotion paradigm was previously reported to be sensitive to medial posterior nucleus accumbens microinjections of the nonselective CCK antagonist proglumide (Crawley, 1988) . In the experiments reported herein, dark-induced hyperlocomotion was quantitated after treatments with CCK-A and CCK-B antagonists, administered intraperitoneally, or microinjected into the After surgery, rats were housed in individual cages within a laminar flow rack, in a temperature-and humidity-controlled vivarium, on a 7 A.M. to 7 P.M. light schedule, with food and water available ad libitum. Behavioral experiments were begun at least 1 week after surgery. Each animal was used twice, with at least I week between uses, and with different treatments on each use. At least eight animals were tested per treatment group. At the end of each experiment, animals were killed and their brains stored in formalin for sectioning, thionin staining, and identification of the track locations by light microscopy.
Microinjections were performed with a 3 1 gauge injection tube, extending 2 mm below the ventral tip of the guide cannula for the anterior and posterior nucleus accumbens, and 3 mm below the ventral tip of the guide cannula for the ventral tegmental area. A volume of 0.2 ~1 per injection site was administered over a I min period, using a Sage microinfusion pump (Orion Instruments, Cambridge, MA), with the injection tube remaining in place for an additional 30 set, before rcmoval of the injection tube and replacement of the stylet. Antagonists or vehicle were administered 5 min before saline, DA, or DA+CCK. Physiological saline (0.9%) was obtained from the NIH Media Supply. Dopamine, 20 fig for the anterior and posterior nucleus accumbens and 3 pg for the ventral tegmental area, prepared in saline vehicle, was obtained from Sigma Chemical Company, St. Louis, MO. Cholecystokinin octapeptide sulfate, IO ng for the anterior and posterior nucleus accumbens and 100 pg for the ventral tegmental area, prepared with dopamine in saline vehicle, was obtained from Bachem Bioscience, Inc., Philadelnhia. PA. Saline. DA. and DA+CCK solutions were oreoared fresh on-the day of the experiment and kept refrigerated throughoit the day. CI-988, 20 ng or 2 pg, prepared fresh in saline vehicle on the day of the experiment, was kindly provided by the Parke-Davis Pharmaceuticals Research Division, Warner-Lambert Company, Ann Arbor, MI. The doses chosen were extrapolated from previous receptor binding studies and behavioral studies using systemically administered Cl-988 (Hughes et al., 1990) . L-364,718 and L-365,260, 10 ng each. prepared primarily in a vehicle of 2.5% propylene glycol, 2.5% ethanol, and 95% warm saline, were kindly provided by thk Merck Sharp and Dohme Research Laboratories. Merck and Comnanv. West Point. PA. The . _ vehicle was chosen for its effectiveness in maintaining benzodiazepines in solution (Crawley and Davis, 1982) and effectiveness in maintaining L-364.718 and L-365.260 in solution CC. Dourish. nersonal commu-. nication). The doses chosen were extrapolated from previous receptor binding studies and behavioral studies using systemically administered L-364,71 8 and L-365,260 (Chang and Lotti, 1986; Khosla and Crawley, 1988 : Dourish et al.. 1989 : Lotti and Chans. 1989 . The hiahest con-1 I centration of L-364.7 18 and of L-365,260 that could be maintained as a warm solution was 10 nd0.2 ~1. One minute after the last of the four microinjections, the rat was placed in a Digiscan Animal Activity Meter (Omnitech Instruments, Columbus, OH) for a 15 min test session. This paradigm was designed to quantitate the rat's initial exploration of a novel environment. Ambulatory activity was chosen as the automated Digiscan parameter that most accurately reflected exploratory locomotion. Each animal was used twice, with different treatments on the two uses, and at least I week between treatment uses. Six to 10 animals were used for each dose of each treatment in each condition. Ambulatory activity data for each l CCK-A/CCK-B Antagonists: Mesolimbic DA Behaviors treatment group were analyzed for significant treatment effects by oneway analysis of variance, followed by a Newman-Keuls test for significance of comparisons between individual means. Dark-induced hyperlocomotion experiments were conducted as previously described (Crawley, 1988) . Rats were cannulated as described above, for microinjections at least 1 week later, into the medial posterior nucleus accumbens, the anterior nucleus accumbens, or the ventral tegmental area. The three CCK antagonists were prepared at the doses described above, in the vehicles described above, for microinjection as described above. In addition, 718, 260 were prepared for intraperitoneal administration over a wide dose range in a volume of 1 ml/kg. The vehicle for CI-988 was 0.9% physiological saline. Several vehicles were tried for L-364,7 18 and L-365,260. Comparison of the 2.5% propylene glycol, 2.5% ethanol, 95% warm saline vehicle with the 0.5% carboxymethylcellulose vehicle (Dourish et al., 1989 ) indicated some inhibitory behavioral activity for the carboxymethylcellulose vehicle; therefore, the ethanol/propylene glycol/saline vehicle was used for subsequent experiments with L-364,7 18 and L-365,260. The highest concentration of L-364,718 and L-365,260 that could be maintained in solution with this vehicle was 100 pg/kg/ml. The dose of 1 mg/kg L-364,7 18 and L-365,260 was therefore prepared as a sonicated suspension in the 0.5% carboxymethylcellulose vehicle.
Immediately after the intracerebral microinjection, or 30 min after intraperitoneal injection ofvehicle or CCK antagonist, the rat was placed in a D&scan Animal Activity Meter linked to an Omnitech Analyzer. The D&can open field was housed within an environmental chamber with the lights on for half of the animals ("light" condition) and the lights off for half of the animals ("dark" condition). No data were collected during the first 5 min after the animal was placed in the Dig&an, to allow for recovery from any stress of the injection procedure. Data were collected during the next 30 min, in 10 min intervals. Horizontal activity was chosen as the automated parameter that most accurately reflected exploratory locomotion in the Omnitech Analyzer data array.
The Dig&an system employed in the light-controlled chamber was linked to a Digiscan computer analyzer that yielded several behavioral parameters. The ambulatory activity parameter shown in the experiments of Figures l--I, which employed an older, non-computer-linked Digiscan system, was not obtainable in the computer-linked D&scan system used for the dark-induced hyperlocomotion experiments of Figures 5-l 2. Histological analysis was performed as described above. Each animal was used twice, with different treatments on the two uses, and at least 1 week between treatment uses. Six to 10 animals were used for each dose of each treatment in each condition. Horizontal activity data for each treatment group were analyzed for significant treatment effects by one-way analysis of variance, followed by a Newman-Keuls test for significance of comparisons between individual means. Comparisons of horizontal activity in the dark versus the light environment, after treatment with different vehicles or no injection, were performed with paired Student's t test.
Results Figure 1 illustrates cannula placements in the medial posterior nucleus accumbens, the anterior nucleus accumbens, and the ventral tegmental area. Placements in the medial posterior nucleus accumbens resided in the anatomical subdivision representing the terminal field of the CCK-DA coexistence from the midbrain DA neurons, as described by Hijkfelt et al. (1980a,b) , and analogous to the subdivision designated as the shell of the accumbens (Heimer et al., 199 1; Deutch and Cameron, 1992) . Placements in the anterior nucleus accumbens were at least 1.5 mm farther rostral, at 2.4-2.8 mm rostra1 to bregma, where the corpus callosum and caudate nucleus first appear. Approximately 7% of the animals cannulated in the two accumbens sites showed incorrect placements; behavioral data from these animals were removed from the statistical analyses. Placements in the ventral tegmental area were consistently localized in the central or caudal levels of the ventral tegmentum. Approximately 9% of the animals cannulated in the ventral tegmental area showed incorrect placements; behavioral data from these animals were removed from the statistical analyses. Figure 3 shows the results of experiments with (J-988 or saline pretreatment 5 min before saline, DA, or DA+CCK into the anterior nucleus accumbens. At the anterior accumbens site, DA induced hyperlocomotion and CCK antagonized DA-induced hyperlocomotion (ANOVA, Fs 51 = 2.77, p < 0.05; Newman-Keuls, p < 0.05 for saline + saline vs saline + DA, p < 0.05 for saline + DA vs saline + DA+CCK). Pretreatment with CI-988 (20 ng) significantly antagonized CCK-induced attenuation of DA-induced hyperlocomotion but had no significant effect on DA-induced hyperlocomotion or baseline saline locomotion (ANOVA as above, F5.5, = 2.77, p < 0.05; NewmanKeuls, NS for comparison of saline + saline vs CI-988 + saline, NS for comparison of saline + DA vs CI-988 + DA, p < 0.05 for comparison of saline + DA+CCK vs CI-988 + DA+CCK). Figure 4 shows the results of experiments with CCK antagonists given 5 min before saline, DA, or DA+CCK, into the ventral tegmental area. At this site, DA induced hypolocomotion, and CCK potentiated DA-induced hypolocomotion (ANOVA, F,,4, = 26.1, p +Z 0.01; Newman-Keuls, p < 0.01 for comparison of vehicle + saline vs vehicle + DA; p < 0.05 for comparison of vehicle + DA vs vehicle + DA+CCK). L-364,7 18 (10 ng) and L-365,260 (10 ng) had no significant effect on baseline locomotion as compared to vehicle + saline (ANO-VA, Fm = 3.30, NS). L-364,718 and L-365,260 had no significant effect on DA-induced hypolocomotion as compared to vehicle + DA (ANOVA, F,,,, = 0.68, NS). L-365,260 significantly antagonized CCK potentiation of DA-induced hypolocomotion, while L-364,7 18 did not (ANOVA, F,.*.,, p < 0.01; Newman-Keuls, p < 0.0 1 for comparison of vehicle + DA+CCK vs L-365,260 + DA+CCK, NS for comparison of vehicle + DA+CCK vs L-364,718 + DA+CCK). CI-988 (20 ng or 2 bg) had no significant effect on baseline saline locomotion as compared to saline + saline treatment (ANOVA, F2,9 = 3.52, NS). CI-988 had no significant effect on DA-induced hypolocomotion as compared to saline + DA (ANOVA, F2,2, = 0.11, NS). CI-988 significantly antagonized CCK potentiation of DA-induced hypolocomotion, at both doses, 20 ng and 2 Fg, as compared to saline + DA+CCK (ANOVA, F2.24 = 3.95, p < 0.05; Horizontal activity was measured in 10 min time blocks over the 30 min test session. Horizontal activity declined over the three consecutive 10 min blocks in both the light and dark conditions. Horizontal activity was significantly higher for the dark condition than the light condition in the first 10 min block only (ANOVA, F,,,, = 5.33, p < 0.0 1; Newman-Keuls, p < 0.05 for light vs dark, O-10 min block). Figure 6 characterizes the dark-induced hyperlocomotion paradigm for uninjected rats and for rats after intraperitoneai, posterior nucleus accumbens, anterior nucleus accumbens, or ventral tegmental area administration of three possible vehicles for the CCK antagonists. The vehicles tested were 0.9% physiological saline, 0.5% carboxymethyiceiiuiose (Dourish et al., 1989) , and 2.5% ethanol, 2.5% propylene giycoi, 95% warm saline (Crawley and Davis, 1982) . Horizontal activity was significantly elevated in the dark Digiscan environment as compared to the light Digiscan environment after intraperitoneai saline treatment (t = 2.81, df = 11, p < 0.02) and after intraperitoneai ethanol/propylene giycoi/saiine treatment (t = 3.02, df = 28, p < 0.01). No significant difference between light and dark conditions was measured in horizontal activity scores after treatment with carboxymethyiceiiuiose vehicle (t = 0.99, df = 21, NS), reflecting lower scores on horizontal activity in the dark, indicating that this vehicle would not be optimal for experiments with L-364,718
and L-365,260 in the dark-induced hyperiocomotion paradigm. In the medial posterior nucleus accumbens, a significant increase in horizontal activity was detected in the dark as compared to in the light, for no microinjection (t = 3.27, df = 12, p < 0.0 i), ethanol/propylene giycoi/saiine microinjection (t = 3.5 1, df = 12, p < O.Oi), and saline microinjection (t = 2.32, df = 8, p < 0.05). In the anterior nucleus accumbens, a significant increase in horizontal activity was detected in the dark as compared to in the light, for saline vehicle microinjection (t = 2.34, df = 7, p < 0.05). In the ventral tegmentai area, a significant increase in horizontal activity was detected in the dark as compared to in the light, for no microinjection (t = 2.84, df = 6, p < 0.05), ethanol/propylene giycoi/saiine microinjection (t = 2.49, df = 8, p < 0.05), and for saline microinjection (t = 2.32, df = 8, p < 0.05). Based on the results of the experiments of Figure 5 , the vehicle chosen for intraperitoneai and intracerebral studies with L-364,718
and L-365,260 was the 2.5% ethanol, 2.5% propylene giycoi, 95% warm saline solution; saline was chosen as the vehicle for experiments with CI-988. Figure 7 shows the lack of effect of intraperitonealiy administered L-364,178 on dark-induced hyperiocomotion.
Intraperitoneai doses of L-364,718 from 100 r&kg to 1 mg/kg had no significant effect on horizontal activity in the light condition as compared to vehicle treatment (ANOVA, F,,,, = 0.52, NS) Similarly, L-364,7 18 had no significant effect on horizontal activity in the dark condition as compared to vehicle treatment (ANO-VA, F,,,, = 2.88, p < 0.05; Newman-Keuis, p < 0.05 for the comparison of 10 &kg vs 1 mg/kg, but no significant differences were detected between vehicle and any dose of L-364,7 18). Figure 7 . Lack of effects of intraperitoneal L-364,7 18 on dark-induced hyperlocomotion. Doses of L-364,718 from 100 &kg to 100 &kg were administered intraperitoneally in a volume of 1 ml/kg in the ethanol/propylene glycol/saline vehicle, 35 min before the start of the 30 min test session. The dose of 1 mg/kg was prepared in 0.5% carboxymethylcellulose. L-364,718 had no significant effect on horizontal activity in either the light or the dark environment at any of the doses tested. Figure 6 . Comparison of vehicle treatments in the dark-induced hyperlocomotion paradigm. Significantly higher cumulative 30 min horizontal activity was displayed by rats in the dark environment as compared to the light environment after no injection, intraperitoneal treatment with saline, and intraperitoneal treatment with 2.5% ethanol, 2.5% propylene glycol, 95% warm saline (*, p < 0.05; **, p < 0.0 1; dark vs light), but not after intraperitoneal treatment with 0.5% carboxymethylcellulose. Dark-induced hyperlocomotion was significant after microinjection of 2.5% ethanol, 2.5% propylene glycol, 95% warm saline, or after 0.9% physiological saline, into the medial posterior nucleus accumbens, the anterior nucleus accumbens, and the ventral tegmental area (WA; *, p < 0.05; **, p < 0.01; dark vs light).
L-365,260
from 100 rig/kg to 1 mg/kg had no significant effect on horizontal activity in the light condition, as compared to vehicle treatment (ANOVA, F4,57 = 0.81, NS). L-365,260 significantly decreased horizontal activity in the dark condition, as compared to vehicle treatment (ANOVA, F6.53 = 7.15, p < 0.01; Newman-Keuls, p < 0.01 for the comparison of 1 mg/kg vs vehicle, p < 0.05 for the comparison of 10 /&kg vs vehicle, p < 0.05 for the comparison of 100 &kg vs vehicle). Figure 9 shows the effects of intraperitoneally administered CI-988 on dark-induced hyperlocomotion. Doses of CI-988 (10 Fg/kg and 1 mg/kg) had no significant effect on horizontal activity in the light condition, as compared to vehicle treatment (F,,,, = 0.59, NS). (X-988 had no significant effect on horizontal activity in the dark condition, as compared to vehicle treatment (FZ,Zb = 0.10, NS). Figure 10 shows the lack of effects of CCK antagonists on dark-induced hyperlocomotion when microinjected into the medial posterior nucleus accumbens. L-364,718
(10 ng), L-365,260 (10 ng), and CI-988 (20 ng or 2 Fg) had no significant effect on horizontal activity in the light condition as compared to ethanol/propylene glycol/saline vehicle or as compared to saline vehicle (ANOVA, F5,38 = 0.73, NS). L-364,718, L-365,260, and CI-988 had no significant effect on horizontal activity in the dark condition as compared to either vehicle (ANOVA, F,,4, = 1.09, NS). Figure 11 shows the lack of effects of CI-988 on dark-induced hyperlocomotion when microinjected into the anterior nucleus accumbens. CI-988 (20 ng or 2 pg) had no significant effect on horizontal activity in the light condition as compared to saline vehicle (ANOVA, F,, = 1.04, NS). CI-988 (20 ng or 2 pg) had no significant effect on horizontal activity in the dark condition as compared to saline vehicle (ANOVA, Fz,18 = 1.30, NS). Figure 12 shows the lack of effects of CCK antagonists on dark-induced hyperlocomotion when microinjected into the ventral tegmental area. L-364,718 (10 ng), L-365,260 (10 ng), and U-988 (20 ng or 2 pg) had no significant effect on horizontal activity in the light condition as compared to ethanol/propylene glycol/saline vehicle or to saline vehicle (ANOVA, F,,39 = 0.5 1, NS). L-364,7 18, L-365,260, and CI-988 had no significant effect on horizontal activity in the dark condition as compared to either vehicle (ANOVA, F,,,, = 1.15, NS). 
Discussion
Previous behavioral studies have demonstrated that CCK potentiates DA-induced hyperlocomotion, amphetamine-induced hyperlocomotion, amphetamine-induced stereotypy, and selfstimulation, when microinjected into the medial posterior nucleus accumbens (Crawley et al., 1985a; De Witte et al., 1987; Weiss et al., 1988; Vaccarino and Rankin, 1989; Vaccarino and Vaccarino, 1989) . A biphasic dose-response curve indicated that picogram to nanogram doses of CCK potentiated DA, while microgram doses had no effect or inhibited DA, in several behavioral paradigms (Widerlov et al., 1983; Crawley et al., 1985a; Britton et al., 1989) . Unsulfated cholecystokinin octapeptide and cholecystokinin tetrapeptide were inactive at doses up to 1000 times the active dose of sulfated cholecystokinin octapeptide, indicating a peripheral-type or CCK-A pharmacology . The present studies demonstrate that a subtype-selective antagonist of the CCK-A receptor, L-364,7 18, effectively antagonized the ability of CCK to potentiate DAinduced hyperlocomotion in the media1 posterior nucleus accumbens. The present results are consistent with recent studies demonstrating a CCK-A receptor subtype mediating CCK po- Figure   9 . Lack of effects of intraperitoneal Cl-988 on dark-induced hyperlocomotion. Doses of (X-988 (IO &kg and 1 mg/kg) were administered intraperitoneally in a volume of 1 ml/kg in saline vehicle, 35 min before the 30 min test session. CI-988 had no significant effect on horizontal activity in either the light or the dark environment at the doses tested. tentiation of DA release from the posterior nucleus accumbens of the rat in vitro (Vickroy et al., 1988; Marshal1 et al., 1991) .
The terminal field of the mesolimbic neurons in which CCK and DA coexist, therefore, appears to utilize a CCK-A mechanism for the actions of CCK in potentiating dopaminergic functions. At variance with this conclusion are neurophysiological studies reporting a CCK-A pharmacology mediating the excitatory effects of CCK in the rat nucleus accumbens, which block the inhibitory effects of dopaminergic agonists in the posterior nucleus accumbens (Wang et al., 1988; Yim and Mogenson, 1991) . CCK-A receptors have been reported in the posterior nucleus accumbens of the cow brain (Barrett et al., 1989) , and in the nucleus accumbens of cynomolgus monkey brain (Graham et al., 199 1) . Inferential evidence suggests the presence of CCK-A receptors in the nucleus accumbens of rat brain (Rovati and Makovec, 1988) . However, no direct autoradiographic or receptor binding assays have detected measurable concentrations of CCK-A receptors in the rat nucleus accumbens to date.
Behavioral studies in our laboratory previously demonstrated that CCK potentiates DA-induced hypolocomotion in the ventral tegmental area (Crawley, 1989b) . Unsulfated CCK octapeptide was active at a dose equimolar to sulfated CCK octapeptide; CCK tetrapeptide was active at a dose just four times greater than the active dose of sulfated CCK octapeptide, and the CCK-B agonist BC 264 was active at this site (Crawley, 1989b; Dauge et al., 1990) . In the present studies, the CCK-B antagonists L-365,260 and U-988 antagonized the potentiating actions of CCK on DA-induced hypolocomotion in the ventral tegmental area. The present behavioral results are consistent with neurophysiological studies showing that unsulfated cholecystokinin octapeptide is approximately as active as sulfated cholecystokinin octapeptide in potentiating apomorphine and DA-induced reductions in neuronal firing in ventral tegmental and substantia nigra neurons (Hommer and Skirboll, 1983; Hommer et al., 1986) . The cell bodies ofthe mesolimbic neurons in which CCK and DA coexist, therefore, appear to utilize a CCK-B mechanism for the actions of CCK in inhibiting dopaminergic functions.
Previous behavioral studies in our laboratory have demonstrated that CCK inhibits or has no effect on DA-induced hyperlocomotion in the anterior nucleus accumbens (Crawley et al., 1985b) . Behavioral studies from other laboratories demonstrated that CCK attenuates amphetamine-induced hyperlocomotion and self-stimulation in the anterior nucleus accumbens (Vaccarino and Rankin, 1989; Vaccarino and Vaccarino, 1989) . In the present studies, the CCK-B antagonist CI-988 antagonized the ability of CCK to inhibit DA-induced hyperlocomotion in the anterior nucleus accumbens. The present behavioral findings are consistent with in vitro release studies indicating a CCK-B receptor mediating the CCK suppression of DA release in the rostra1 nucleus accumbens ( bit neurons in which CCK and DA do not coexist, therefore, appears to utilize a CCK-B mechanism for the modulatory actions of CCK in inhibiting dopaminergic functions.
The present studies provide the first information on active doses of L-364,7 18, L-365,260, and Cl-988 for microinjection studies in the rat mesolimbic pathway. Several caveats must be considered in interpreting the present data. Solubility limitations are a serious consideration for microinjection studies of CCK antagonists. Given the small volumes used in microinjection studies (e.g., 0.2 J), compounds need to be prepared in high concentrations (e.g., 1 mg/ml) to allow testing of the upper regions of a dose-response curve (e.g., 200 ng/0.2 ~1). CI-988 is water soluble, such that two divergent doses, 20 ng and 2 pg, could be tested in the present studies. However, L-364,7 18 and L-365,260 are not water soluble; therefore, a vehicle must be chosen that dissolves or suspends the compound for accurate dosing, and that itself has minimal biological activity. Concentrated dimethyl sulfoxide and concentrated ethanol are often used as vehicles in biochemical experiments, but may have behavioral effects when microinjected into the brain. Carboxymethylcellulose (0.5%) the vehicle used to suspend L-364,7 18 and L-365,260 for systemic injections (Dourish et al., 1989) . is relatively viscous.
In the present experiments, the 0.5% carboxymethylcellulose suspensions with L-364,7 18 and L-365,260 often clogged the 31 gauge injection tubes used in the present experiments. The warmed solution of 2.5% ethanol, 2.5% pro-* CCK-A/CCK-6
Antagonists: Mesolimbic DA Behaviors pylene glycol, 95% saline, used previously in studies of benzodiazepines (Crawley and Davis, 1982) , maintained both L-364,7 18 and L-365,260 in solution at doses up to 10 ng/0.2 ~1, but higher concentrations did not remain in solution. The present studies therefore do not represent dose-response curves, but employed the highest dose of L-364,7 18 and of L-365,260 that could be maintained in solution. The dose of 10 nd0.2 ~1 is consistent with extrapolations from the active doses of L-364,7 18 and L-365,260 given systemically (Dourish et al., 1989) , given the ability of these compounds to diffuse through tissue rapidly and to cross the blood-brain barrier (Pullen and Hodgson, 1987) . However, the lack of effects of 10 ng/0.2 ~1 L-364,71 8 in the ventral tegmental area and the anterior nucleus accumbens, and the trend toward but lack of significant effects of 10 r&0.2 ~1 L-365,260 in the medial posterior nucleus accumbens, must be interpreted with caution. It is possible that higher doses of these compounds would inhibit the behavioral actions of CCK. Complete dose-response studies are necessary to evaluate definitively the relative potencies of CCK-A versus CCK-B antagonists in the medial posterior nucleus accumbens, anterior nucleus accumbens, and ventral tegmental area. Development of more soluble CCK-A antagonists will be required to conduct complete dose-response curves. The data obtained herein on the differential actions of L-364,7 18 and L-365,260 (10 ng/0.2 Al), combined with the differential actions of the water-soluble CCK-B antagonist CI-988 at the three anatomical sites, can be considered as preliminary indications of differential receptor subtype involvement in the behavioral effects of CCK at these three sites.
At the doses tested, no significant effects of L-364,718, L-365,260, or CI-988 were seen when microinjected 5 min before saline into the medial posterior nucleus accumbens, anterior nucleus accumbens, or ventral tegmental area. A trend toward reduction in ambulatory activity was seen for L-364,718 + saline, L-365,260 + saline, and CI-988 + saline, as compared to saline + saline, after microinjections into the ventral tegmental area. These three trends did not reach statistical significance, perhaps due to the larger variance in these treatment groups than in others, and/or the smaller number of animals with correct cannula placements in these groups (N = 5-7) as compared to other groups (N = 6-l 0). The possibility that CCK antagonists reduce exploratory activity when microinjected into the ventral tegmental area is not supported by the results of the dark-induced hyperlocomotion experiments discussed below.
At the doses used, no significant effects of L-364,718, L-365,260, or CI-988 were seen when microinjected 5 min before DA, into the medial posterior nucleus accumbens, anterior nucleus accumbens, or ventral tegmental area. There was a trend for CI-988 to reduce DA-induced hyperlocomotion in the anterior nucleus accumbens. This trend did not reach statistical significance using one-way ANOVA with Newman-Keuls comparison of CI-988 + DA versus saline + DA. It may be important to note that the hyperlocomotion induced by DA in the anterior nucleus accumbens was of a somewhat smaller magnitude than the hyperlocomotion induced by DA in the medial posterior nucleus accumbens.
The general lack of effect of these three CCK antagonists on baseline (saline vehicle) exploratory activity, and on DA-induced hyperlocomotion and hypolocomotion, is relevant to the issue of the contribution of endogenous mesolimbic CCK to exploratory activity. A current hypothesis of the functional activity of coexisting neurotransmitters is the frequency coding hypothesis (Bartfai et al., 1988) . As reported for coexisting peptides and catecholamines in peripheral neurons, the "classical" neurotransmitter is released at low frequencies of electrical or chemical stimulation, while the peptide cotransmitter is released along with the "classical" transmitter at higher frequencies of electrical or chemical stimulation. It is possible that a high frequency of neuronal activity is required for the release of endogenous CCK from terminals of the mesolimbic DA pathway. Microinjection of DA may produce hyperlocomotion by activating postsynaptic receptors in the nucleus accumbens, without activating presynaptic release of endogenous DA and CCK. Treatment with a presynaptic activator such as amphetamine or electrical stimulation of the ventral tegmental area may be more likely to cause presynaptic release of endogenous DA and CCK. A behavioral event must therefore activate mesolimbic neurons up to a sufficiently high rate of firing to release endogenous CCK, before an effect of a CCK antagonist can be detected.
In an attempt to design a behavioral paradigm that would maximally activate mesolimbic neurons, we developed the darkinduced hyperlocomotion paradigm. Horizontal activity of rats in the Digiscan in a dark chamber was at least 50% higher than horizontal activity of rats in the Digiscan in a light chamber. Other computer-generated Digiscan Analyzer parameters of exploratory activity, including total distance and vertical activity, also increased in the dark; however, the horizontal activity parameter was found to be the most robust and reliable indicator of dark-induced hyperlocomotion. Qualitatively and quantitatively, the dark-induced increase in horizontal activity is similar to that seen after microinjection of DA into the medial posterior nucleus accumbens, but avoids the use of pharmacological agents that might directly interfere with synaptic release of the cotransmitters. As seen in Figure 5 , the dark environment causes a greater amount of horizontal activity, significant in the first 10 min block of the 30 min test session. The pattern of greater activity during the first 10 min in the dark may be indicative of the less aversive nature of the novel open field when the open field is in the dark, as compared to when the open field is in the light, a phenomenon well characterized in several animal models of anxiety (Crawley, 1989a) . One previous study with the darkinduced hyperlocomotion paradigm detected a decrease in darkinduced hyperlocomotion after microinjection of high doses of the nonselective CCK antagonist proglumide into the medial posterior nucleus accumbens (Crawley, 1988) . The dark-induced hyperlocomotion paradigm was therefore chosen to evaluate the new, highly selective, potent CCK antagonists, in the medial posterior nucleus accumbens, anterior nucleus accumbens, and ventral tegmental area. Further, the three CCK antagonists were also administered systemically in the dark-induced hyperlocomotion paradigm, to determine the net effect of a CCK-A or CCK-B antagonist that might act simultaneously at several anatomical sites in the brain and periphery. Effects of systemically administered CCK antagonists in rats might be predictive of effects that would be obtained with these compounds administered systemically to humans.
L-364,7 18 had no effect on horizontal activity when administered intraperitoneally over a wide dose range (100 &kg to 1 mg/kg) in either the light or the dark environment. Similarly, (X-988 had no significant effect on horizontal activity when administered intraperitoneally at doses of 10 pg/kg or 1 m&kg, in either the light or the dark environment. L-365,260 treatment showed a significant decrease in horizontal activity at intraperitoneal doses of 10 r&kg, 10 &kg, and 1 mgkg, in the dark environment only. The decrease in exploratory activity at these intraperitoneal doses of L-365,260 may be meaningful, and requires further investigation. However, the lack of a dose-related function, the lack of effects of intracerebrally administered L-365,260, and previous reports that systemic L-365,260 increases rather than decreases motor activity in a feeding paradigm (Dourish et al., 1989) suggest that the present data may be artifactual. In particular, the highest dose of L-365,260 and L-364,7 18 (1 mg/kg i.p.) had to be prepared in the 0.5% carboxymethylcellulose vehicle, which inhibited dark-induced hyperlocomotion when administered intraperitoneally alone (Fig. 6) . Thus, behavioral effects shown for the dose of L-365,260 that produced the most significant decrease in horizontal activity in the dark may have been confounded by a vehicle effect. A similar trend was seen for reduced horizontal activity in the dark after L-364,7 18 (1 mg/kg i.p.) in 0.5% carboxymethylcellulose vehicle; however, this difference was not significant.
Systemic administration of CCK antagonists is likely to affect several anatomical sites simultaneously, possibly producing opposite effects at different sites, the sum of which might be zero. Since CCK produced qualitatively different modulatory effects on DA-induced changes in exploratory behavior in the medial posterior nucleus accumbens, as compared to the anterior nucleus accumbens, and as compared to the ventral tegmental area, it was possible that subtype-selective antagonists would differentially affect dark-induced hyperlocomotion at discrete anatomical sites. Microinjections into the medial posterior nucleus accumbens showed no effect of 718, 260, , at the doses tested, on horizontal activity in either the light or the dark environment. Microinjections into the anterior nucleus accumbens showed no effect of CI-988, at the doses of 20 ng or 2 pg, on horizontal activity in either the light or the dark environment. Microinjections in the ventral tegmental area showed no effect of L-364,718, L-365,260, or (J-988 , at the doses tested, on horizontal activity in either the light or the dark environment. These findings are in contradiction with the previous finding that high doses of proglumide, microinjected into the medial posterior nucleus accumbens, partially blocked darkinduced hyperlocomotion (Crawley, 1988) . In the previous study, proglumide may have blocked dark-induced hyperlocomotion through a nonspecific, non-CCK receptor-mediated action. Alternatively, in the present study, insufficient doses of the selective CCK antagonists may have been used. Arguing against the latter interpretation are the data from Figures 2-4 , demonstrating that the same doses of CCK antagonists effectively blocked the modulatory actions of exogenously administered CCK.
The lack of effect of CCK antagonists on a 15 min session of exploratory activity, and on a 30 min session of dark-induced hyperlocomotion, is consistent with the interpretation that endogenous CCK does not contribute to exploratory locomotion in the mesolimbic pathway. This finding may indicate that released endogenous CCK does not play a critical role in maintaining high levels of exploratory behaviors. Alternatively, the behavioral paradigms chosen for the present studies may not be sufficient to activate mesolimbic DA neurons to the extent required to release endogenous CCK, according to the frequency coding hypothesis described above. In particular, the dark-induced hyperlocomotion paradigm may not be sufficiently activating to release endogenous CCK, or sufficiently sensitive to detect contributions of a small amount of released endogenous CCK. Further pharmacological characterization of the darkinduced hyperlocomotion paradigm, using D, and D, agonists and antagonists, may be necessary to determine the relative contribution of the mesolimbic pathway versus other neurotransmitter systems to dark-induced hyperlocomotion. Different behavioral paradigms may be necessary to detect measurable effects of CCK antagonists in the cell body or terminal field regions of the mesolimbic neurons in which CCK and DA coexist, to determine the role ofendogenous CCK in the behavioral output of the mesolimbic system. In vivo studies of co-release of CCK and DA may be a useful approach to address these issues.
In conclusion, highly selective CCK antagonists block the modulatory actions of exogenously administered CCK on exploratory locomotor behavior, differentially at discrete anatomical sites. The CCK-A antagonist L-364,7 18 effectively blocked the ability of CCK to potentiate DA-induced hyperlocomotion in the medial posterior nucleus accumbens. The CCK-B antagonist CI-988 effectively blocked the ability of CCK to inhibit DA-induced hyperlocomotion in the anterior nucleus accumbens. The CCK-B antagonists L-365,260 and CI-988 effectively blocked the ability of CCK to potentiate DA-induced hypolocomotion in the ventral tegmental area. These findings are consistent with previous behavioral studies using subtype-selective CCK fragments, and with in vitro biochemical studies of CCK modulation of DA release from the anterior and posterior nu-cleus accumbens Vickroy et al., 1988; Altar and Boyar, 1989; Crawley, 1989b; Marshall et al., 199 1) . A CCK-B receptor subtype appears to mediate the actions of CCK in the anterior nucleus accumbens and ventral tegmental area, while a CCK-A receptor subtype appears to mediate the actions of CCK in the medial posterior nucleus accumbens. In addition, the present data provide information on active doses, vehicles, and routes of administration of the new CCK antagonists for future intracerebral microinjection studies. The recent availability of potent, subtype-selective, nonpeptide CCK antagonists raises the possibility of designing CCK-based drugs to treat disorders of dopaminergic function that are confined to specific sites within the mesolimbic pathway.
